Studies have shown that PTEN loss is associated with poor survival in stage III melanoma, and genomic alterations in PTEN are linked to protein loss, potentially predicting intrinsic resistance to BRAF inhibitor therapy. The gene discussed is PTEN; the disease is melanoma.